8-K: Glaukos Reports Record First Quarter Sales, Raises Full-Year Revenue Guidance

Glaukos Corporation announced record net sales for the first quarter of 2024, driven by strong performance in both glaucoma and corneal health segments, and subsequently raised its full-year revenue guidance.

Summary

• Glaukos Corporation reported record net sales of $85.6 million for the first quarter of 2024, a 16% increase year-over-year.
• Glaucoma net sales reached a record $67.2 million, up 20% year-over-year, while Corneal Health net sales were $18.4 million, a 4% increase year-over-year.
• The company's gross margin was approximately 76%, with a non-GAAP gross margin of approximately 83%.
• Glaukos has raised its 2024 net sales guidance to a range of $357 million to $365 million, up from the previous range of $350 million to $360 million.
• The company experienced a loss from operations of $39.1 million, and a net loss of $40.8 million, or ($0.82) per diluted share.
• Non-GAAP loss from operations was $32.8 million, and non-GAAP net loss was $34.6 million, or ($0.70) per diluted share.
• The company ended the quarter with approximately $279 million in cash, cash equivalents, short-term investments, and restricted cash.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record sales, increased revenue guidance, and successful product launches. However, the losses and increased expenses temper the overall outlook, resulting in a score of 8.

Positives

• Record net sales were achieved in the first quarter of 2024, demonstrating strong growth.
• Glaucoma and Corneal Health segments both showed positive year-over-year growth.
• The company's gross margin remained strong at approximately 76%, with a non-GAAP gross margin of approximately 83%.
• Full-year revenue guidance was increased, reflecting confidence in future performance.
• The initial commercial launch of iDose TR is underway with positive early feedback.
• Positive reimbursement developments for iDose TR, including a permanent J-code and APC assignment, are expected to improve patient access and streamline payments.
• International Glaucoma sales showed strong growth, indicating successful expansion efforts.
• The company has made significant investments in R&D, supporting a robust pipeline of novel therapies.

Negatives

• The company reported a loss from operations of $39.1 million and a net loss of $40.8 million for the first quarter of 2024.
• Non-GAAP loss from operations was $32.8 million, and non-GAAP net loss was $34.6 million.
• Selling, general, and administrative expenses increased by 16% year-over-year.
• The company experienced a decrease in cash and cash equivalents from $93.5 million to $42.5 million during the quarter.
• The entry into the Medicaid Drug Rebate Program is expected to impact Photrexa realized revenues.
• The company recorded an acquired in-process R&D (IPR&D) charge of $11.7 million.

Risks

• The company faces uncertainties regarding the impact of the COVID-19 pandemic or other public health crises on its business.
• General macroeconomic conditions, including foreign currency fluctuations, could affect the company's performance.
• Reduced physician fee and ASC facility fee reimbursement rates for procedures utilizing the company's iStent family of products could impact revenue.
• The company depends on a limited number of third-party suppliers, some of which are single-source, for components of its products.
• A disruption at the company's primary facility could materially affect manufacturing capacity and operations.
• Securing and maintaining adequate coverage and reimbursement by third-party payors for procedures using the company's products is crucial.
• The company faces competition in the medical device industry, including from current and future MIGS technologies.
• The company must comply with federal, state, and foreign laws and regulations for the approval and sale of its products.
• The clinical trial process is lengthy and expensive, with uncertain timing and outcomes.
• There is a risk of recalls or serious safety issues with the company's products and uncertainty of patient outcomes.
• Protecting the company's intellectual property is expensive and time-consuming.
• The company's ability to service its indebtedness is a risk.

Future Outlook

Glaukos expects full-year 2024 global consolidated net sales of $357 $365 million, with potential contributions from iStent infinite and iDose TR, which are expected to be more significant in the latter part of 2024 into 2025. The company also anticipates potential ordering pattern volatility within its U.S. Glaucoma franchise during the first half of 2024 due to uncertainty associated with MAC LCDs and continued impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery.

Management Comments

• Our record first quarter results reflect successful global execution of our key strategic plans, said Thomas Burns, Glaukos chairman and chief executive officer.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Industry Context

Glaukos' results reflect a growing trend in the ophthalmic industry towards minimally invasive surgical options and sustained-release drug delivery systems. The company's focus on glaucoma, corneal disorders, and retinal diseases aligns with the increasing prevalence of these conditions and the demand for innovative treatments. The successful launch of iDose TR and the continued growth of the iStent portfolio position Glaukos as a key player in the market.

Comparison to Industry Standards

• Glaukos' 16% year-over-year revenue growth in Q1 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• The 20% growth in glaucoma sales is particularly notable, indicating a strong market acceptance of their MIGS devices, which is higher than the average growth rate for glaucoma treatments.
• The non-GAAP gross margin of 83% is competitive with other medical device companies focused on high-value, innovative products.
• Companies like Alcon and Johnson & Johnson Vision, which also operate in the ophthalmic space, have similar gross margins but may have different growth profiles due to their broader product portfolios.
• The launch of iDose TR positions Glaukos as a leader in sustained-release drug delivery for glaucoma, a space where companies like Allergan (now part of AbbVie) have also invested, but Glaukos' approach is unique with its micro-invasive delivery method.
• The company's R&D investment of approximately $600 million since 2018 is significant and demonstrates a commitment to innovation, which is comparable to other leading medical device companies.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and strong sales growth.
• Employees may benefit from the company's growth and continued investment in R&D.
• Customers (ophthalmic surgeons) will have access to new and innovative treatment options.
• Patients will benefit from the availability of new therapies for glaucoma, corneal disorders, and retinal diseases.
• Suppliers may see increased demand for their products as Glaukos expands its operations.

Next Steps

• Continue commercial launch activities for iDose TR.
• Advance patient enrollment in the PMA pivotal trial for iStent infinite.
• Advance patient enrollment in the first-in-human Retina XR clinical development program.
• Advance patient enrollment in the Phase 2a clinical trial for iLution Travoprost.
• Progress towards trial completion for the second Phase 3 confirmatory pivotal trial for Epioxa.
• Prepare to commence the Phase 3 clinical trial for iDose TREX by the end of 2024.
• Continue to secure coverage for commercial and Medicare Advantage plans for iDose TR.
• Continue regulatory submissions and approvals in Latin America for PRESERFLO MicroShunt.

Key Dates

Keywords

Glaukos, Glaucoma, Corneal Health, Ophthalmic, MIGS, iStent, iDose TR, Photrexa, Medical Technology, Pharmaceuticals, Revenue, Gross Margin, R&D, Reimbursement, Clinical Trials